144 ·Filed Jun 1, 2026

ANAB

ANAPTYSBIO, INC
BEARISH
Impact 5/10
Horizondays Processed4mo ago SEC0001950047-26-005454
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

The officer has been a consistent seller over the past two weeks, disposing of over 80,000 shares. While the Form 144 amount is modest relative to market cap, the pattern of sustained selling by an insider warrants monitoring for any upcoming negative catalyst or earnings miss.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
ANAB ▲ +13.15% at T+60d
SHORT call ✗ call lost -13.15% · α vs SPY -12.03% · entry $51.26 → $58.00
Entry anchored
Jun 1, 2026
via day open
T+1d
-0.04%
call +0.04% · α -0.68%
$51.24
settled 4mo ago
T+5d
+0.72%
call -0.72% · α -3.69%
$51.63
settled 4mo ago
T+20d
+27.64%
call -27.64% · α -29.21%
$65.43
settled 3mo ago
T+60d
+13.15%
call -13.15% · α -12.03%
$58.00
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 1, 2026, indicating intent to sell 7,691 shares of common stock valued at approximately $404,340. This follows a series of recent open-market sales by Mulroy totaling over 80,000 shares in the prior two weeks, suggesting a pattern of insider monetization.

Key Facts

  • Officer Dennis Mulroy filed Form 144 to sell 7,691 shares valued at ~$404,340.
  • Mulroy has sold 80,731 shares in open-market transactions from May 15 to May 29, 2026, totaling ~$4.8M.
  • The proposed sale is via Morgan Stanley Smith Barney LLC.
  • Shares were acquired via stock option exercise on June 1, 2026.
  • AnaptysBio has a market cap of $1.6B and 89% analyst bullish consensus.

Financial Impact

Proposed sale of $404K; cumulative recent sales by officer exceed $5M.

insider selling volume

Risk Factors

  • Insider selling ahead of potential negative news or clinical data.
  • Further unannounced sales may pressure the stock.
  • Pattern may signal lack of confidence in near-term prospects despite bullish analyst consensus.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005454
Document: 0001950047-26-005454-index.html0001950047-26-005454
Document: 0001950047-26-005454.txt0001950047-26-005454
24 reports for ANAB
Performance horizon
65% Hit rate 11 of 17 directional calls best @ T+60▲ +41.26%Mar 3, 2026
Filters
Rows
Reports for ANAB — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$56.02 $53.87▼ −3.84%▼ −2.09%$48.53 (−13.37%)
Jun 29, 2026
13w ago
144
BEARISH ★ 6/10
$67.50 $53.61▲ +20.58%▲ +19.55%$48.53 (+28.10%)
Jun 29, 2026
13w ago
DEFA14A
NEUTRAL ★ 2/10
$67.50 $53.61▼ −20.58%▼ −19.55%$48.53 (−28.10%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$65.97 $54.15▲ +17.92%▲ +17.64%$48.53 (+26.44%)
Jun 22, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$59.43 $50.29▼ −15.38%▼ −16.54%$48.53 (−18.34%)
Jun 17, 2026
15w ago
144
BEARISH ★ 5/10
$57.51 $54.15▲ +5.84%▲ +6.38%$48.53 (+15.61%)
Jun 15, 2026
15w ago
144
BEARISH ★ 6/10
$57.61 $62.51▼ −8.51%▼ −8.31%$48.53 (+15.76%)
Jun 11, 2026
16w ago
144
BEARISH ★ 6/10
$56.07 $66.39▼ −18.41%▼ −16.63%$48.53 (+13.45%)
Jun 10, 2026
16w ago
144
BEARISH ★ 5/10
$54.24 $66.59▼ −22.77%▼ −20.88%$48.53 (+10.53%)
Jun 8, 2026
16w ago
144
BEARISH ★ 5/10
$51.63 $67.33▼ −30.40%▼ −28.95%$48.53 (+6.00%)
Showing 10 of 24

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access